Searched for
ASTRAZENECAPHARMA INDIA LTD
AstraZeneca's Enhertu gets regulatory approval in India for first-line HER2-positive breast cancerAstraZeneca Pharma India has secured approval from India's drug regulator for its smart chemotherapy drug Enhertu. This allows for its impo...- AstraZeneca India plans to sell 64-acre Bengaluru site for Rs 3,400 croreThe land parcel, expected to fetch about ₹3,400 crore for AstraZeneca Pharma India, has drawn interest from developers including the Sattva...
- AstraZeneca Pharma India surrenders marketing authorisation of prostate cancer drugAstraZeneca Pharma India has voluntarily surrendered the marketing authorisation for its prostate cancer drug Olaparib (Lynparza) 100mg and...
- AstraZeneca Pharma India plans to sell Bengaluru plantThe company will position the manufacturing site for sale in a fully operational manner and begin a search for a buyer who can also act as ...
- AstraZeneca Pharma India Q2 results: Net profit declines 55% to Rs 12 crIts revenue from operations during July-September 2021 stood at Rs 197.70 crore. It was Rs 209.47 crore for the same period a year ago, it ...
- AstraZeneca Pharma India moves Delhi High Court against NPPA demand noticeThe notice of demand alleges that the company has overcharged about Rs 157.38 crore during the period from March 8, 2019 to January 31, 202...
- AstraZeneca Pharma India Q3 results: Net profit declines 21% to Rs 21 crRevenue from operations of the company stood at Rs 200.25 crore for the quarter under consideration. It was Rs 223.86 crore for the same pe...
- AstraZeneca Pharma gets DCGI nod to market asthma drugAstraZeneca Pharma said the receipt of this permission paves way for the launch of Benralizumab (Fasenra) in India, subject to the receipt ...
- AstraZeneca Pharma India Q1 results: Net profit declines 13% at Rs 18.63 croreDrug firm AstraZeneca Pharma India on Monday reported a 13.38 per cent decline in its net profit to Rs 18.63 crore for the quarter ended Ju...
- AstraZeneca Pharma India gets DCGI nod to market diabetes drugThe product is indicated as an adjunct therapy to diet and exercise to improve glycemic control in adults with type 2 diabetes, AstraZeneca...
- AstraZeneca Pharma India appoints Gagan Singh Bedi as MDThe company has accepted resignation of Sanjay Murdeshwar as MD and as a director. He is shifting to a global role within the AstraZeneca g...
- AstraZeneca Q3 net profit at Rs 8.67 croreStandalone total income of the company stood at Rs 144.58 crore for the quarter. It was Rs 108.20 crore for the year ago period.
- AstraZeneca Pharma India to close Bengaluru API unitDrug firm AstraZeneca Pharma India will close its Active Pharmaceutical Ingredient (API) unit at Bengaluru due to low demand for the produc...
- AstraZeneca Pharma India posts Q1 net profit of Rs 2.71 croreAstraZeneca Pharma India today reported a standalone net profit of Rs 2.71 crore for the first quarter ended June 30, 2015.
- AstraZeneca Pharma India reports third quarter net loss at Rs 13.40 croreAstraZeneca Pharma India today reported a standalone net loss of Rs 13.40 crore for the third quarter ended December 2014.
- AstraZeneca Pharma board approves delisting of company's shares from stock exchangesAstraZeneca Pharma today said its board has approved delisting of the company's shares from bourses, including BSE and the National Stock E...
- AstraZeneca Pharma shares rise 3 per cent on board's approved delisitngShares of AstraZeneca Pharma rose by 3 per cent as its board has approved delisting of the company's shares from bourses like NSE, BSE etc.
- Buy AstraZeneca Pharma India Ltd with a target of Rs 870: Ashwani Gujral"AstraZeneca Pharma India Ltd is a ‘BUY’ call with a target of Rs 870 and a stop loss of Rs 825."
- Sell Astrazeneca Pharma India Ltd with a target of Rs 600: Prakash Gaba"Astrazeneca Pharma India Ltd is a ‘SELL’ call with a target of Rs 600 and a stop loss of Rs 700."
- Buy AstraZeneca Pharma with a target of 1860: Sandeep WagleAstraZeneca Pharma India Ltd is a ‘BUY’ call with a target of Rs 1860 and a stop loss of Rs 1680.
Load More
